Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer (CIK) cells: implications for their infusion across major HLA barriers-Reference-Cited by-同舟云学术

Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer (CIK) cells: implications for their infusion across major HLA barriers

Published:2008-05-09 Issue:7 Volume:20 Page:841-848
ISSN:1460-2377
Container-title:International Immunology
language:en
Short-container-title:

Author:

Sangiolo Dario,Martinuzzi Emanuela,Todorovic Maja,Vitaggio Katiuscia,Vallario Antonella,Jordaney Noela,Carnevale-Schianca Fabrizio,Capaldi Antonio,Geuna Massimo,Casorzo Laura,Nash Richard A.,Aglietta Massimo,Cignetti Alessandro

Publisher

Oxford University Press (OUP)

Subject

Immunology,General Medicine,Immunology and Allergy

Link

http://academic.oup.com/intimm/article-pdf/20/7/841/18322341/dxn042.pdf

Reference29 articles.

1. Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production;Baker;Blood,2001

2. Tissue-specific segregation of CD1d-dependent and CD1d-independent NK T cells;Eberl;J. Immunol.,1999

3. A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency;Lu;J. Immunol.,1994

4. Propagation of large numbers of T cells with natural killer cell markers;Schmidt-Wolf;Br. J. Haematol,1994

5. Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice;Hoyle;Blood,1998

Cited by 103 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Potential alternatives to αβ-T cells to prevent graft-versus-host disease (GvHD) in allogeneic chimeric antigen receptor (CAR)-based cancer immunotherapy: A comprehensive review;Pathology - Research and Practice;2024-10

2. CAR products from novel sources: a new avenue for the breakthrough in cancer immunotherapy;Frontiers in Immunology;2024-04-11

3. Allogeneic CAR-T Therapy Technologies: Has the Promise Been Met?;Cells;2024-01-12

4. CSPG4 CAR-redirected Cytokine Induced Killer lymphocytes (CIK) as effective cellular immunotherapy for HLA class I defective melanoma;Journal of Experimental & Clinical Cancer Research;2023-11-22

5. The effect of serum origin on cytokines induced killer cell expansion and function;BMC Immunology;2023-09-01